Genomic Analyses for Elucidating Novel Targets for Symptoms Management

用于阐明症状管理新目标的基因组分析

基本信息

项目摘要

Most symptoms are multifactorial in origin with both genetic and environmental factors contributing to individual variations. Candidate gene studies on the basis of biological hypotheses have been performed to identify relevant genetic variation in complex traits such as pain. However, the complicated mesh of contributing factors and the thousands of molecules involved in different symptoms makes it difficult to detect responsible genetic variations for an individuals unique susceptibility to disorders. It is unlikely that common variations in a single gene act dominantly on complex traits; rather, the contribution of each gene seems to be subtle, acting on one of multiple biological pathways, making its signal difficult to detect. The combined impact of the rapid increase in knowledge of diseases and the ability to apply powerful and high capacity technology has raised expectations for more effective and safer medicines for various types of symptoms management. Developing new treatment strategies for symptoms management is also critically dependent on identifying new target molecules and defining phenotypes for specific types of disorders. Therefore the first step of this project has been to define the characteristics of experimental and clinical phenotypes. Recently, we launched multiple projects with next generation sequencing (NGS) technology, which allows us to perform entire and/or targeted genome sequencing. The role of genetic and epigenetic factors on symptoms in various disorders and/or conditions will continue to be studied. For example, in neurological disorders such as acute pain, mild traumatic brain injury and PTSD, we are using genotyping, gene and protein expression, and patient reported outcomes to better understand the reciprocal interplay between these factors and the numerous biologic/mechanistic pathways including the inflammatory cascade. Gene expression profiles from the soldiers back from war zone were presented at the multiple meetings (CNRM and ASN meeting) and have been submitted for publication. Two epigenetic studies using DNA methylation chromatin immunoprecipitation followed by whole genome scale sequencing were conducted from civilian and military groups. Epigenetic changes in the sports related concussion patients will be presented at the ASHG meeting. The second epigenetic study in military PTSD patients finished sequencing of samples and the data are under the analysis. Using the targeted next generation sequencing technology, we also have 2 on-going microbiome projects to characterize population of microorganisms in human and/or animal body from different disease status. Using a next generation semiconductor sequencer, microbiome was analyzed with extensive sequencing of 16s rRNA region in an animal model of irritable bowel syndrome and human patients. The results were presented at the scientific meeting and submitted for publication. Another microbiome project was launched recently for oral microbiome from the aplastic anemia patients. So far, preliminary data analysis was finished and its result will be presented at the IADR meeting. Additional samples will be sequenced and analyzed. Mainly both projects found that the microbiome composition is altered in specific disease conditions. Developing new analyzing methods for the high throughput big data generated by the next generation sequencers is another goal of these projects. From these results along with biological knowledge of multiple pathways in neurological disorders, we will be able to suggest molecular-genetic mechanisms of those diseases at the level of the individual. Finally, we can suggest integrative genomic analysis to develop new drugs and test them based on individual genetic information.
大多数症状是多因素的起源与遗传和环境因素有助于个体差异。基于生物学假设的候选基因研究已经被用来确定复杂性状(如疼痛)的相关遗传变异。然而,复杂的影响因素和参与不同症状的数千种分子使得很难检测出个体对疾病独特易感性的遗传变异。单个基因的共同变异不太可能对复杂性状起主导作用;相反,每个基因的作用似乎很微妙,作用于多个生物途径中的一个,使其信号难以检测。 疾病知识的迅速增长和应用强大和高容量技术的能力的综合影响,提高了人们对用于各种症状管理的更有效和更安全的药物的期望。开发用于症状管理的新治疗策略也关键地依赖于识别新的靶分子和定义特定类型的病症的表型。因此,该项目的第一步是确定实验和临床表型的特征。 最近,我们启动了多个采用下一代测序(NGS)技术的项目,该技术使我们能够进行整个和/或靶向基因组测序。将继续研究遗传和表观遗传因素对各种疾病和/或病症症状的作用。 例如,在神经系统疾病,如急性疼痛,轻度创伤性脑损伤和创伤后应激障碍,我们正在使用基因分型,基因和蛋白质表达,以及患者报告的结果,以更好地了解这些因素之间的相互作用和众多的生物/机械途径,包括炎症级联反应。从战区回来的士兵的基因表达谱在多个会议(CNRM和ESTA会议)上提出,并已提交出版。两个表观遗传学研究使用DNA甲基化染色质免疫沉淀,然后全基因组规模测序进行了从平民和军事群体。运动相关脑震荡患者的表观遗传变化将在ASHG会议上介绍。第二次军人创伤后应激障碍患者表观遗传学研究已完成样本测序,数据正在分析中。使用靶向下一代测序技术,我们还有2个正在进行的微生物组项目,以表征人类和/或动物体内不同疾病状态的微生物群体。使用下一代半导体测序仪,通过对肠易激综合征动物模型和人类患者的16 s rRNA区域进行广泛测序来分析微生物组。研究结果在科学会议上作了介绍,并提交出版。另一个微生物组项目最近启动了再生障碍性贫血患者的口腔微生物组。到目前为止,初步的数据分析已经完成,其结果将在IADR会议上公布。将对其他样本进行测序和分析。主要是这两个项目发现,微生物组组成在特定疾病条件下发生变化。为下一代测序仪产生的高通量大数据开发新的分析方法是这些项目的另一个目标。 从这些结果沿着的生物学知识的多个途径的神经系统疾病,我们将能够建议这些疾病的分子遗传机制在个人的水平。最后,我们可以建议综合基因组分析来开发新药,并根据个体遗传信息进行测试。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ann Cashion其他文献

Ann Cashion的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ann Cashion', 18)}}的其他基金

Genomic Analyses for Elucidating Novel Targets for Symptoms Management
用于阐明症状管理新目标的基因组分析
  • 批准号:
    9148043
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
Genomic Approaches for Elucidating Novel Targets for Pain and Symptom Management
阐明疼痛和症状管理新靶标的基因组方法
  • 批准号:
    8554728
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
NINR Intramural Research Training Programs
NINR 校内研究培训计划
  • 批准号:
    8735593
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
Molecular-Genetic Mechs Underlying Effects of Anti-inflammatory/Analgesic Drugs
抗炎/镇痛药物作用的分子遗传学机制
  • 批准号:
    8554727
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
Genomic Analyses for Elucidating Novel Targets for Symptoms Management
用于阐明症状管理新目标的基因组分析
  • 批准号:
    8735582
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
NINR Intramural Research Training Programs
NINR 校内研究培训计划
  • 批准号:
    8940189
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
Genomic Analyses for Elucidating Novel Targets for Symptoms Management
用于阐明症状管理新目标的基因组分析
  • 批准号:
    9554462
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
NINR Intramural Research Training Programs
NINR 校内研究培训计划
  • 批准号:
    8554737
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
Molecular-Genetic Mechs Underlying Effects of Anti-inflammatory/Analgesic Drugs
抗炎/镇痛药物作用的分子遗传学机制
  • 批准号:
    8735581
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:
Biomarkers to Predict Patient Outcomes and Guide Therapies
预测患者结果并指导治疗的生物标志物
  • 批准号:
    8940029
  • 财政年份:
  • 资助金额:
    $ 93.23万
  • 项目类别:

相似海外基金

Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
  • 批准号:
    10778757
  • 财政年份:
    2023
  • 资助金额:
    $ 93.23万
  • 项目类别:
Selective actin remodeling of sensory neurons for acute pain management
感觉神经元的选择性肌动蛋白重塑用于急性疼痛管理
  • 批准号:
    10603436
  • 财政年份:
    2023
  • 资助金额:
    $ 93.23万
  • 项目类别:
Clinical Outcome Assessments for Acute Pain Therapeutics in Infants and young Children (COA APTIC)
婴幼儿急性疼痛治疗的临床结果评估 (COA APTIC)
  • 批准号:
    10783106
  • 财政年份:
    2023
  • 资助金额:
    $ 93.23万
  • 项目类别:
Development of A Focused Ultrasound Device for Noninvasive, Peripheral Nerve Blockade to Manage Acute Pain
开发用于非侵入性周围神经阻断来治疗急性疼痛的聚焦超声装置
  • 批准号:
    10740796
  • 财政年份:
    2023
  • 资助金额:
    $ 93.23万
  • 项目类别:
Predicting Pediatric Sickle Cell Disease Acute Pain Using Mathematical Models Based on mHealth Data
使用基于移动健康数据的数学模型预测儿童镰状细胞病急性疼痛
  • 批准号:
    10599401
  • 财政年份:
    2022
  • 资助金额:
    $ 93.23万
  • 项目类别:
Non-Contingent Acute Pain Stress Drives Analgesic Protection in Rats.
非偶然急性疼痛应激驱动大鼠镇痛保护。
  • 批准号:
    575854-2022
  • 财政年份:
    2022
  • 资助金额:
    $ 93.23万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Master's
Prefrontal Cortex Hemodynamic Responses to Mindfulness Meditation and Acute Pain
前额皮质血流动力学对正念冥想和急性疼痛的反应
  • 批准号:
    467076
  • 财政年份:
    2021
  • 资助金额:
    $ 93.23万
  • 项目类别:
    Studentship Programs
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
  • 批准号:
    9979265
  • 财政年份:
    2020
  • 资助金额:
    $ 93.23万
  • 项目类别:
Endocannabinoid Metabolism in Acute Pain
急性疼痛中的内源性大麻素代谢
  • 批准号:
    10356880
  • 财政年份:
    2020
  • 资助金额:
    $ 93.23万
  • 项目类别:
A Multimodal Approach for Monitoring Prolonged Acute Pain in Neonates
监测新生儿长期急性疼痛的多模式方法
  • 批准号:
    10218273
  • 财政年份:
    2020
  • 资助金额:
    $ 93.23万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了